+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Targeted Therapy Drugs for Melanoma Market by Mechanism of Action (BRAF Inhibitors, CTLA-4 Inhibitors, MEK Inhibitors), Route of Administration (Intravenous, Oral), Treatment Line, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Targeted Therapy Drugs for Melanoma Market by Mechanism of Action (BRAF Inhibitors, CTLA-4 Inhibitors, MEK Inhibitors), Route of Administration (Intravenous, Oral), Treatment Line, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Sale

Targeted Therapy Drugs for Melanoma Market by Mechanism of Action (BRAF Inhibitors, CTLA-4 Inhibitors, MEK Inhibitors), Route of Administration (Intravenous, Oral), Treatment Line, Distribution Channel, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 182 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6079690
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The melanoma targeted therapy market is undergoing a period of unprecedented transformation, marked by rapid advancements in precision medicine, evolving clinical guidelines, and shifting global regulatory and manufacturing landscapes. Senior stakeholders now face a dynamic environment where strategic decisions must account for new molecular therapies, cost structures, and regional uptake.

Market Snapshot: Trends and Growth Drivers in Melanoma Targeted Therapy

Melanoma targeted therapy has entered a new era fueled by precision-driven drug development, breakthrough immuno-oncology agents, and widespread adoption of genomic profiling. Recent clinical integration of BRAF, MEK, CTLA-4, and PD-1 inhibitors has redefined treatment standards. These targeted approaches now underpin improved survival outcomes, reshaping both care protocols and market demand. Across mature and emerging regions, there is accelerated uptake of combination regimens supported by evolving diagnostic workflows and robust pipelines. Strategic collaborations, regulatory shifts, and new tariff measures affecting pharmaceutical imports are also influencing market access and pricing, driving attention toward value-based reimbursement models and supply chain resilience.

Scope & Segmentation: In-Depth Coverage Across Key Market Dimensions

  • Mechanism of Action: BRAF inhibitors (Dabrafenib, Encorafenib, Vemurafenib), CTLA-4 inhibitors (Ipilimumab), MEK inhibitors (Binimetinib, Cobimetinib, Trametinib), PD-1 inhibitors (Nivolumab, Pembrolizumab)
  • Route of Administration: Intravenous and oral formulations, accommodating both hospital-based infusions and at-home therapies for convenience and improved adherence
  • Treatment Line: First-line, second-line, and third-line or beyond, each with unique adoption trends and clinical response priorities
  • Distribution Channel: Hospital pharmacy, online pharmacy, and retail pharmacy—reflecting diverse procurement needs, specialty dispensing, and chronic therapy delivery
  • End User: Ambulatory surgical centers, hospitals, and oncology centers, each with distinct formulary dynamics and resource requirements
  • Geographic Coverage: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, and others), Asia-Pacific (including China, India, Japan, Australia, and more)
  • Key Companies Tracked: Novartis AG, F. Hoffmann-La Roche Ltd, Pfizer Inc., Genentech, Inc., Array BioPharma LLC

Key Takeaways: Strategic Insights for Senior Decision-Makers

  • Precision-targeted therapies are now central to melanoma care, replacing older broad-spectrum treatments and enabling personalized, molecularly guided interventions.
  • The adoption of combination regimens leveraging BRAF/MEK inhibitors and immune checkpoint inhibitors is rising, driven by the need to overcome resistance and prolong durable response.
  • Regional adoption is influenced by regulatory clarity, reimbursement structures, and local investment in diagnostic and manufacturing capacity, creating nuanced opportunities and challenges across markets.
  • Advanced diagnostics—such as digital pathology and biomarker-driven tools—streamline patient selection and are increasingly integrated into care delivery and trial enrollment strategies.
  • Ongoing collaborations between pharma innovators, academic centers, and diagnostic developers foster iterative therapy optimization and rapid adaptation to real-world evidence.
  • Companies investing in digital health, patient support platforms, and supply chain diversification are best positioned to navigate evolving cost structures and policy changes.

Tariff Impact: Managing Cost and Supply Chain Complexity

The implementation of new United States tariffs in 2025 has directly affected pharmaceutical inputs critical for melanoma targeted therapies. Manufacturers reliant on specialized imports now face higher expenses and longer procurement cycles, prompting increased nearshoring and domestic production investments. These developments drive transitional shifts in capacity planning, while also pushing reimbursement frameworks toward outcome-linked and value-based models. Stakeholders must actively monitor future changes to trade policy and incentive programs.

Methodology & Data Sources

This report integrates primary expert interviews with oncologists and industry leaders, extensive secondary research from literature, conference proceedings, and regulatory filings. Data triangulation across company disclosures, clinical trial registries, and proprietary databases ensures accuracy. Validation processes include subject matter peer review and advanced analytical techniques for trend mapping and benchmarking.

Why This Report Matters

  • Delivers a comprehensive, actionable overview for executives making strategic decisions in R&D, commercialization, and market access for melanoma targeted therapies.
  • Facilitates proactive planning around tariffs, reimbursement evolution, and technology adoption to protect competitive positioning and operational excellence.

Conclusion

The melanoma targeted therapy landscape is rapidly evolving, shaped by innovations in precision medicine, regulatory adaptation, and market dynamics. Stakeholders who align strategy with emerging clinical, economic, and regional realities will be well positioned for sustained growth and patient impact.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of next-generation sequencing for personalized BRAF and MEK inhibitor selection in melanoma patients
5.2. Advancements in third-generation BRAF inhibitors demonstrating improved blood-brain barrier penetration in metastatic melanoma
5.3. Clinical trial data supporting triplet therapy combining BRAF, MEK, and immune checkpoint inhibitors in advanced melanoma
5.4. Development of resistance biomarkers guiding adaptive dosing strategies for targeted melanoma therapies
5.5. Cost-effectiveness analyses of novel targeted regimens in adjuvant treatment settings for high-risk melanoma
5.6. Growing investment in tumor genotyping platforms accelerating targeted therapy adoption in early-stage melanoma management
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Targeted Therapy Drugs for Melanoma Market, by Mechanism Of Action
8.1. Introduction
8.2. BRAF Inhibitors
8.2.1. Dabrafenib
8.2.2. Encorafenib
8.2.3. Vemurafenib
8.3. CTLA-4 Inhibitors
8.3.1. Ipilimumab
8.4. MEK Inhibitors
8.4.1. Binimetinib
8.4.2. Cobimetinib
8.4.3. Trametinib
8.5. PD-1 Inhibitors
8.5.1. Nivolumab
8.5.2. Pembrolizumab
9. Targeted Therapy Drugs for Melanoma Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
10. Targeted Therapy Drugs for Melanoma Market, by Treatment Line
10.1. Introduction
10.2. First Line
10.3. Second Line
10.4. Third Line And Beyond
11. Targeted Therapy Drugs for Melanoma Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Targeted Therapy Drugs for Melanoma Market, by End User
12.1. Introduction
12.2. Ambulatory Surgical Center
12.3. Hospital
12.4. Oncology Center
13. Americas Targeted Therapy Drugs for Melanoma Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Targeted Therapy Drugs for Melanoma Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Targeted Therapy Drugs for Melanoma Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Novartis AG
16.3.2. F. Hoffmann-La Roche Ltd
16.3.3. Pfizer Inc.
16.3.4. Genentech, Inc.
16.3.5. Array BioPharma LLC
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. TARGETED THERAPY DRUGS FOR MELANOMA MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. TARGETED THERAPY DRUGS FOR MELANOMA MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. TARGETED THERAPY DRUGS FOR MELANOMA MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. TARGETED THERAPY DRUGS FOR MELANOMA MARKET: RESEARCHAI
FIGURE 26. TARGETED THERAPY DRUGS FOR MELANOMA MARKET: RESEARCHSTATISTICS
FIGURE 27. TARGETED THERAPY DRUGS FOR MELANOMA MARKET: RESEARCHCONTACTS
FIGURE 28. TARGETED THERAPY DRUGS FOR MELANOMA MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. TARGETED THERAPY DRUGS FOR MELANOMA MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DABRAFENIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DABRAFENIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ENCORAFENIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ENCORAFENIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY VEMURAFENIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY VEMURAFENIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY IPILIMUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY IPILIMUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BINIMETINIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BINIMETINIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COBIMETINIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COBIMETINIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TRAMETINIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TRAMETINIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY NIVOLUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ONCOLOGY CENTER, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ONCOLOGY CENTER, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 115. CANADA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 116. CANADA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 117. CANADA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 118. CANADA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 119. CANADA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 120. CANADA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 121. CANADA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 122. CANADA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 123. CANADA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 124. CANADA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 125. CANADA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 126. CANADA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 127. CANADA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 128. CANADA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 129. CANADA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 130. CANADA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 131. CANADA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 132. CANADA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 133. MEXICO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 134. MEXICO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 135. MEXICO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 136. MEXICO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 137. MEXICO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 138. MEXICO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 139. MEXICO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 140. MEXICO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 141. MEXICO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 142. MEXICO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 143. MEXICO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 144. MEXICO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 145. MEXICO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 146. MEXICO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 147. MEXICO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. MEXICO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. MEXICO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 150. MEXICO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 151. BRAZIL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 152. BRAZIL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 153. BRAZIL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 154. BRAZIL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 155. BRAZIL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 156. BRAZIL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 169. ARGENTINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 170. ARGENTINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 171. ARGENTINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 172. ARGENTINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 173. ARGENTINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 174. ARGENTINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 175. ARGENTINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 176. ARGENTINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 177. ARGENTINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 178. ARGENTINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 185. ARGENTINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 186. ARGENTINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 208. UNITED KINGDOM TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 210. UNITED KINGDOM TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 212. UNITED KINGDOM TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 214. UNITED KINGDOM TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 216. UNITED KINGDOM TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 218. UNITED KINGDOM TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 220. UNITED KINGDOM TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 222. UNITED KINGDOM TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 224. UNITED KINGDOM TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 225. GERMANY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 226. GERMANY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 227. GERMANY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 228. GERMANY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 229. GERMANY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 230. GERMANY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 231. GERMANY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 232. GERMANY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 233. GERMANY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 234. GERMANY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 235. GERMANY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 236. GERMANY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 237. GERMANY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 238. GERMANY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 239. GERMANY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 240. GERMANY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 241. GERMANY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 242. GERMANY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 243. FRANCE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 244. FRANCE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 245. FRANCE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 246. FRANCE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 247. FRANCE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 248. FRANCE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 249. FRANCE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 250. FRANCE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 251. FRANCE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 252. FRANCE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 253. FRANCE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 254. FRANCE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 255. FRANCE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 256. FRANCE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 257. FRANCE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 258. FRANCE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 259. FRANCE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 260. FRANCE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 261. RUSSIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 262. RUSSIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 263. RUSSIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 264. RUSSIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 265. RUSSIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 266. RUSSIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 267. RUSSIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 268. RUSSIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 269. RUSSIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 270. RUSSIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 271. RUSSIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 272. RUSSIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 273. RUSSIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 274. RUSSIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 275. RUSSIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 276. RUSSIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 277. RUSSIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 278. RUSSIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 279. ITALY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 280. ITALY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 281. ITALY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 282. ITALY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 283. ITALY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 284. ITALY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 285. ITALY TARGETED THERAPY DRUGS FOR MELANOMA

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Targeted Therapy Drugs for Melanoma market report include:
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • Genentech, Inc.
  • Array BioPharma LLC

Related Topics

Related Reports

Combination Therapies for Melanoma Market by Combination Regimen Type, Line of Therapy, Disease Stage, Administration Route, End User - Global Forecast 2025-2030 - Product Image

Combination Therapies for Melanoma Market by Combination Regimen Type, Line of Therapy, Disease Stage, Administration Route, End User - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
MEK Inhibitor Market by Indication (Colorectal Cancer, Melanoma, Non-Small Cell Lung Cancer), Product (Binimetinib, Cobimetinib, Selumetinib), Application, Line of Therapy, Route of Administration, Distribution Channel - Global Forecast 2025-2030 - Product Image

MEK Inhibitor Market by Indication (Colorectal Cancer, Melanoma, Non-Small Cell Lung Cancer), Product (Binimetinib, Cobimetinib, Selumetinib), Application, Line of Therapy, Route of Administration, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 191 Pages
  • Global
From
MEK Inhibitors - Global Strategic Business Report - Product Image

MEK Inhibitors - Global Strategic Business Report

  • Report
  • 132 Pages
  • Global
From
Untreated Metastatic Or Unresectable Melanoma- Pipeline Insight, 2025 - Product Image

Untreated Metastatic Or Unresectable Melanoma- Pipeline Insight, 2025

  • Drug Pipelines
  • 80 Pages
  • Global
From
Advanced Melanoma - Pipeline Insight, 2025 - Product Image

Advanced Melanoma - Pipeline Insight, 2025

  • Drug Pipelines
  • 180 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.